机译:手术切除在HR-NBL1 / SIOPEN试验中引入CH14.18 / CHO免疫疗法后重新出生的高危神经母细胞瘤生存的影响
St Anna Kinderforsch eV S2IRP Studies &
Stat Integrated Res &
Projects Vienna Austria;
St Anna Kinderkrebsforsch Childrens Canc Res Inst Studies &
Stat Integrated Res &
Projects;
Paris Descartes Univ Necker Enfants Malad Hosp Dept Pediat Surg Paris France;
Oslo Univ Hosp Paediat Surg Oslo Norway;
Univ Hosp Padua Paediat Surg Padua Italy;
Hosp Univ La FE Paediat Oncol Valencia Spain;
Karolinska Inst Astrid Lindgren Childrens Hosp Paediat Oncol Stockholm Sweden;
Univ Hosp Lausanne Paediat Oncol Lausanne Switzerland;
Fdn IRCCS Inst Nazl Tumori Paediat Oncol Milan Italy;
Hosp Univ La FE Paediat Oncol Valencia Spain;
Schneider Childrens Med Ctr Israel Paediat Oncol &
Haematol Petah Tiqwa Israel;
Agia Sofia Childrens Hosp Dept Paediat Oncol &
Haematol Athens Greece;
Univ Hosp Motol Dept Paediat Oncol &
Haematol Prague Czech Republic;
Jagiellonian Univ Med Coll Dept Paediat Oncol &
Haematol Krakow Poland;
Univ Dublin Dept Paediat Oncol &
Haematol Dublin Ireland;
Ernst Moritz Arndt Univ Greifswald Dept Paediat Oncol &
Haematol Greifswald Germany;
Univ Hosp Ghent Dept Paediat Oncol &
Haematol Ghent Belgium;
Inst Gustave Roussy Dept Paediat Oncol &
Haematol Villejuif France;
Inst Canc Res &
Royal Marsden NHS Trust Dept Paediat Oncol &
Haematol Sutton Surrey England;
St George Hosp Paediat Surg London England;
机译:手术切除在HR-NBL1 / SIOPEN试验中引入CH14.18 / CHO免疫疗法后重新出生的高危神经母细胞瘤生存的影响
机译:HR-NBL1 / Siopen试验中的抗GD2抗体CH14.18 / CHO +/-IL2的免疫疗法改善了高危神经母细胞瘤患者的结果与历史控制相比
机译:HR-NBL1 / Siopen试验中的抗GD2抗体CH14.18 / CHO +/-IL2的免疫疗法改善了高危神经母细胞瘤患者的结果与历史控制相比
机译:在基于SIOPEN的高危神经母细胞瘤1试验(HR-NBL1)中使用基于Dinutuximab Beta的免疫治疗的研究
机译:手术切除手术切除对4阶段高危神经母细胞瘤患者存活的影响:HR-NBL1 / SIOPEN研究中的报告